Synthesis and activity of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl) acetamide analogues as anticolitis agents via dual inhibition of TNF-α- and IL-6-induced cell adhesions

Tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) are the critical pro-inflammatory cytokines involved in the pathogenesis of inflammatory bowel disease (IBD). Inhibition of these cytokines and related signaling pathways has been a target for the development of IBD therapeutics. In the current study, 6-acetamido2,4,5-trimethylpyridin-3-ol (1) and various analogues with the amido scaffold were synthesized and examined for their inhibitory activities in in vitro and in vivo IBD models. The parent compound 1 (1 mu M) showed an inhibitory activity against TNF-alpha- and IL-6-induced adhesion of monocytes to colon epithelial cells, which was similar to tofacitinib (1 mu M), a JAK inhibitor, but much better than mesalazine (1,000 mu M). All the analogues showed a positive relationship (R-2 = 0.8943 in a linear regression model) between the inhibitory activities against TNF-alpha-induced and those against IL-6-induced adhesion. Compound 2-19 turned out to be the best analogue and showed much better inhibitory activity against TNF-alpha- and IL-6-induced adhesion of the cells than tofacitinib. In addition, oral administration of compound 1 and 2-19 resulted in a significant suppression of clinical signs of TNBS-induced rat colitis, including weight loss, colon tissue edema, and myeloperoxidase activity, a marker for inflammatory cell infiltration in colon tissues. More importantly, compound 2-19 (1 mg/kg) was more efficacious in ameliorating colitis than compound 1 and sulfasalazine (300 mg/kg), the commonly prescribed oral IBD drug. Taken together, the results suggest that compound 2-19 can be a novel platform for dual-acting IBD drug discovery targeting both TNF-alpha and IL-6 signaling.

Automated summary

TNF-alpha and IL-6 are critical pro-inflammatory cytokines in the pathogenesis of inflammatory bowel disease (IBD). The compound 2-19 showed superior inhibitory activity against TNF-alpha and IL-6-induced cell adhesion, and was more effective in ameliorating colitis compared to traditional IBD drugs. Compound 2-19 could serve as a novel platform for dual-acting IBD drug discovery targeting both TNF-alpha and IL-6 signaling pathways.